Clinical Trials Logo

Chronic Myelogenous Leukaemia clinical trials

View clinical trials related to Chronic Myelogenous Leukaemia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03205267 Recruiting - Clinical trials for Chronic Myelogenous Leukaemia

Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients

BODO
Start date: March 2016
Phase: Phase 2
Study type: Interventional

Bosutinib is a 2nd generation tyrosine kinase inhibitor that has shown promising results from first up to fourth line treatment in patients with in chronic phase of chronic myelogenous leukaemia. Most patients discontinuing the treatment with Bosutinib do so because of side effects occuring early after starting the treatment. A step in dosing scheme could improve these early toxicities. The aim of this study therefore is to demonstrate that temporary lowering of the Bosutinib dose during early treatment may help to reduce or prevent side effects while preserving efficacy.